Table 3. Characteristics of adult patients living with SLE in Sweden identified from the Swedish National Patient Register.
| All patients(n=7490) | SLE without psoriasis(n=7123) | SLE with psoriasis(n=367) | P value | |
|---|---|---|---|---|
| Variable | ||||
| Female sex, n (%) | 6497 (86.7) | 6193 (86.9) | 304 (82.3) | 0.03 |
| SLE diagnosis, year interval | ||||
| 1969–2000, n (%) | 1134 (15.1) | 1075 (15.1) | 59 (16.1) | |
| 2001–2010, n (%) | 3067 (40.9) | 2908 (40.8) | 159 (43.3) | |
| 2011–2022, n (%) | 3289 (43.9) | 3140 (44.1) | 149 (40.6) | |
| Age in 2022, mean (SD, range), years | 59.0 (17.5, 18–104.2) | 58.8 (17.5, 18.0–104.3) | 63.6 (15.9, 22.7–95.6) | <0.001 |
| Disease duration SLE, mean (SD, range), years | 16.5 (10.8, 1.0–53.8) | 16.5 (10.8, 1.0–53.8) | 17.1 (10.6, 1.0–52.9) | 0.25 |
| Disease duration psoriasis, mean (SD, range), years | N/A | N/A | 13.3 (7.8, 0.3–39.8) | |
| Immunomodulating therapies, dispensed year 2005–2022 | ||||
| Antimalarials, n (%) | 5711 (76.2) | 5446 (76.5) | 265 (70.5) | 0.06 |
| Methotrexate, n (%) | 1903 (25.4) | 1735 (24.4) | 168 (44.7) | <0.0001 |
| TNF inhibitors, n (%) | 214 (2.9) | 180 (2.5) | 34 (9.0) | <0.0001 |
| Other biologics*, n (%) | 346 (4.6) | 311 (4.4) | 35 (9.3) | <0.0001 |
| JAK inhibitors, n (%) | 51 (0.7) | 42 (0.6) | 9 (2.4) | 0.0007 |
| Other immunosuppressants†, n (%) | 3401 (45.4) | 3233 (45.4) | 168 (44.7) | 0.9 |
| Immunomodulating therapies, dispensed 2021–2022 | ||||
| Antimalarials, n (%) | 4030 (53.8) | 3869 (54.3) | 161 (43.9) | <0.0001 |
| Methotrexate, n (%) | 836 (11.2) | 764 (10.7) | 72 (19.6) | <0.0001 |
| TNF inhibitors, n (%) | 76 (1.0) | 66 (0.9) | 10 (2.7) | 0.004 |
| Other biologics*, n (%) | 249 (3.3) | 44 (0.6) | 21 (5.7) | <0.0001 |
| JAK inhibitors, n (%) | 34 (0.5) | 0 (0.0) | 7 (1.9) | N/A |
| Other immunosuppressives†, n (%) | 1842 (24.6) | 1765 (24.8) | 78 (21.3) | 0.1 |
*
Subgroup consisting of abatacept, anifrolumab, bimekizumab, belimumab, brodalumab, guselkumab, intravenous immunoglobulin, ixekizumab, risankizumab, rituximab, secukinumab, tildrakizumab and ustekinumab.
†
Subgroup consisting of azathioprine, cyclosporin A, cyclophosphamide, leflunomide, everolimus, mycophenolic acid, sirolimus, sulfasalazine, tacrolimus and voclosporin.
JAK, Janus kinase; N/A, not applicable; TNF, tumour necrosis factor.